InformexUSA 2013 in Review . . . . . . . . . . . . 3SOCMA Expansion Fuels Advocacy Effort . . . 4

Five Minutes With…Jordi Robinson, global head, technical

business development, Navine Flourine International . . . . . . . . . . . . . . . . . . . . . . . . 7

Paul N . Wituschek, VP, global business development, Catalent . . . . . . . . . . . . . . . . 9

John Rice, executive director, The Chemical Education Foundation . . . . 13

Wrap Party Toasts 2013 InformexUSA . . . . . 19

Showcase Snapshots . . . . . . . . . . . . . . . . . . . 20

Exhibitor News . . . . . . . . . . . . . . . . . . . . . . 5–21

Exhibitor Photos . . . . . . . . . . . . . . . . . . . . . . . 22

Advertiser Index . . . . . . . . . . . . . . . . . . . . . . . 21

See To Sell or Not page 18

An all-expert panel debating the issues facing Rx-360 included, from left to right, Tom Beil, VP, quality and regulatory affairs, Sigma / Alrich / SAFC; Kim Cauchy, VP, global sourcing, Mylan;

and William Reis, VP, global strategic sourcing, Amgen

Mission Possible: Rx-360’s Vital Role

What vendor issues keep senior

pharmaceutical procurement professionals

up at night, and how does Rx-360 help

to bridge the gaps between pharmaceutical companies

and their suppliers?

That was the gist of a panel discussion Thursday

designed to illustrate Rx-360’s role in helping to secure

the pharmaceutical supply chain from the perspectives

of corporate and government entities.

Session moderator Scott Watson, executive director

and sales and marketing/membership chair of Rx-360,

See Rx-360 page 18

To Sell or Not—When, Where and How

The value of a business may be much more than

what meets the eye. Business owners have much

to learn from a professional valuation expert

when they decide to sell their businesses. Experts on a

Thursday morning session on “Business Valuation and

the Exit Planning and Sale of Business Process”

Allen Oppenheimer, president of O.M. Oppenheimer,

a 30-year-old business brokerage, valuation expert, and

exit planning strategy company, explained that there are

two reasons to get a business evaluation—internal, for

estate planning, and external, for selling the business.

The evaluation is designed to substantiate the intangible

part of the business’s value, to differentiate between the

“book equity” and the total value of the company to

help the seller get paid for it, Oppenheimer said.

http://www.ampacfinechemicals.com

INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 3

The 29th annual Informex concluded last week with a highly motivated

and qualified audience spending four days in Anaheim immersed in

discovering the latest innovations, trends, and services for the global

chemical marketplace. With 89 percent of the attendees being able to authorize

or recommend purchases, there were thousands of meetings taking place and

partnerships being forged to further the product development and contract

manufacturing plans of the Informex audience.

Other key highlights for this event included: n Top fine chemical product development teams in attendance from the

pharmaceutical and bio technology sectored included: Abbvie, Allergan, Amgen,

Eli Lilly, Gilead, Mylan, Pfizer, Roche, Sanofi, and Sigma-Aldrich.

n Specialty chemicals were being sourced by top executives from AkzoNobel,

Cargill, Dow Argosciences, Dupont, Eastman, ExxonMobil, Honeywell,

Huntsman, Lubrizol, Shell, and Sherwin-Williams

Being in Anaheim, Informex attracted new attendees to this sourcing and

business event, with 32 percent of the audience being first time attendees. This

edition of Informex also had international visitors drawing 34 percent of the

attendees from outside the U.S.

Informex offered more educational programming this year designed to help

attendees with their sourcing and project plans. Sessions of high interest included

Perspectives on the Specialty Chemicals Market; Attn Suppliers: What Keeps

Me Up at Night—How Rx-360 Helps Me Sleep Better; President’s panel on “API

Manufacturing in U.S. is Dead or is it?; and Non-cGMP Manufacturing: What I Look

for in a Toller.

The numerous networking events—hallmarks of Informex— were well attended

and many attendees leveraged these opportunities to strengthen their business

relationships and partnerships.

“We met with many of the Informex advisory board members and key customers

at this year’s Informex and have a renewed sense of purpose and commitment to

developing an even higher quality event for our 30th anniversary in Miami,” said

Daniel Read, portfolio director, UBM Live, the owners and organizer of Informex.

“Their insight, as well as on-going discussions and intelligence gathering with all

sectors of the business, will help us continue to best serve the industry and develop

important platforms that connect the industry in unique and valuable ways.”

Informex 2014 will take place Jan. 21-24, 2014 at the Miami Beach Convention

Center in Miami, FL.

Visit informex.com for more information on all of the brand’s offerings.

Publisher Kenneth M. CarrollEditor Sharon Donovan

Reporter Ilene SchneiderArt Director Connie HameediPhotographers Peter Cutts

Advertising Sales USA Dean Baldwin, Robert LaPointe,

Thomas Scanlan

Europe Uwe Riemeyer, Paul Barrett, Nadia Liefsoens

Asia Minghua Lu, Angel Zu, Mai Hashikura, Shigamaro Yatsui,

Faredoon Kuka

Production Manager Joseph Davis

ACS Publications Advertising Sales Group

480 East Swedesford Road Wayne, PA 19087

Phone 610.964.8061/Fax 610.964.8071

http://cen.acs.org/onsite.html

P u b l i s h e d b y A m e r i c a n C h e m i c a l S o c i e t y

Meetings, Sourcing, Education Top Agenda at InformEx Strong Purchasing Power Of Attendees

Left to right, Michael Feighery, sales manager, InformEx, and Daniel Read, portfolio director, UBM Live, owners and organizers of InformEx

4 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California

Market Expansion, Competitiveness Highlight SOCMA’s 2013 Advocacy Efforts

With more than 90 new

members and the 113th

Congress preparing to

tackle key legislative issues in the

coming year, the Society of Chemical

Manufacturers and Affiliates

(SOCMA) kicked off its “First 100

Days” initiative Jan. 20 to educate

Congress about issues important to the

specialty chemical industry.

Specifically, SOCMA plans to

advocate for policies to help American

companies be more competitive and

expand their markets. “The government

can do things that can severely harm

our industry’s competitiveness, such

as overregulation and outdated tax

systems, but it can also help us better

compete by strengthening policies that

make growth and innovation a top

priority,” said Bill Allmond, SOCMA’s VP,

government and public relations.

Throughout the 100 days, SOCMA’s

Government Relations team will visit

new members of Congress on Capitol

Hill, as well as various agencies, to

introduce the organization and share

SOCMA’s position on issues such as

regulatory reform; taxes, including the

R&D tax credit; intellectual property

and confidential business information

protection; trade issues, including the

Miscellaneous Tariff Bill and free trade

agreements; chemical security; and

many others.

SOCMA CONNECT’s 6th Annual

Washington Fly-In, set for April 9-10,

is also included in the First 100 Days

initiative. The Fly-In is an opportunity

for SOCMA members to visit Capitol

Hill and talk face-to-face with members

of Congress and their staff to ensure

that elected officials consider the issues

and challenges facing the specialty

chemical industry when voting on

legislation.

As part of the First 100 Days effort,

SOCMA also plans to assist members

in scheduling site visits at their facilities

with members of Congress and

encourage members to write letters to

elected officials regarding the sector’s

top priorities, among other activities.

Visit SOCMA at Booth 2357.

SOCMA members met on the steps of the U.S. Capitol before discussing issues important to the specialty chemical industry with senators and representatives during SOCMA CONNECT’s annual Washington Fly-In.

Site visits like this one at SOCMA member Nation Ford Chemical will be a part of SOCMA’s First 100 Days initiative. From left, representative Mick Mulvaney, Nation Ford Chemical VP Phillip McCarter, and Nation Ford president Jay Dickson.

INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 5

AFC Production Capacity Increases 30 PercentAMPAC Fine Chemicals (AFC) manufactures active pharmaceutical ingredients

(APIs) and registered intermediates for customers in the pharmaceutical industry.

Its integrated facilities are located in Rancho Cordova, CA, approximately 20

miles east of downtown Sacramento, and in La Porte, TX, approximately 28

miles east of Houston.

With more than 50 years of experience in mastering challenging chemistries,

AMPAC has developed capabilities that support processes and technologies.

Its products are manufactured in compliance with the U.S. Food and Drug

Administration’s current Good Manufacturing Practices.

AFC is a wholly owned subsidiary of American Pacific (AMPAC), a company

with divisions that also manufacture specialty chemicals used in aerospace

and national defense programs, fire protection, water treatment, and other

commercial applications.

With the La Porte expansion, AFC’s total production capacity has been

increased approximately 30 percent, or up to approximately 256m3 (68,000

gallons), with reactors from 20 to 16,000 L (5 to 4,000 gallons).

AFC’s California facility includes four Class 100,000-rated buildings.

Highlights include two commercial-scale continuous simulated moving bed

(SMB) units, a Class 100,000 solids handling and drying facility, three self-

contained, high-containment facilities, remote facilities for conducting hazardous

operations, including a semi-continuous diazomethane system and three

production facilities with azide processing capability.

Visit AMPAC at ww.ampacfinechemicals.com.

Making Products More Durable With Chemtura ChemistryChemtura, a global specialty chemicals company, builds the chemistry that makes

other products more durable, safer, cleaner and more efficient. Major industries

served include transportation, energy and electronics, and agriculture.

With global headquarters in Philadelphia, it manufactures products in 14

countries and sells products in more than 100 countries. With approximately 4,300

employees in research, manufacturing, sales, and administrative facilities in markets

of the world, it operates regional headquarters and shared service centers in the

U.S., Brazil, China, the U.K., and Switzerland.

Among its global initiatives:

n One of the two largest global marketers and sellers of recreational water

products used in pools and spas (Consumer Products)

n A leading niche developer and manufacturer of seed treatments, fungicides,

miticides, insecticides, growth regulants, and herbicides

n One of the three largest developers and manufacturers of bromine and bromine-

based products (Great Lakes Solutions); and of organometallic compounds, that

have applications in catalysts, surface treatment, and pharmaceuticals

It is a global manufacturer and marketer of: high-performance additive components,

building blocks for synthetic lubricant base-stocks; calcium sulfonate specialty greases

and phosphate and polyol ester-based fluids; and hot cast elastomers. The hallmarks of

its businesses include differentiation through technology, investing in sustainable tech-

nologies and applications, increased exposure to higher-growth regions, an expanded

global footprint and infrastructure, greater customer focus and intimacy, and stewardship

of its products and their use. Visit Chemtura at www.chemtura.com.

6 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California

Contract Research Organization Has More than 200 PatentsAn international and independent group and a custom synthesis supplier, Fabbrica

Italiana Sintetici (FIS) Group is committed to developing, producing, and

delivering active ingredients, key intermediates, advanced intermediates, and

building blocks for the pharmaceutical industry.

With more than 50 years of experience, FIS Group offers an integrated service

to end-users from R&D to full scale production and from grams to tons; a diversifed

team for multiple needs; financial resources to invest for specific projects; and a

personalized, efficient approach for every customer.

As a private Italian contract research organization that specializes in active

pharmaceutical ingredients (API) production, custom synthesis is its core business for

pharmaceutical companies under confidentiality agreements. FIS has the capability to

provide integrated services to the customer, including process research and development,

optimization, and scale-up facilities to support both validation and commercial launch.

With two production plants in Italy and three offices abroad, FIS develops and sells

numerous generic APIs including anxiolytics, anticonvulsants, antidepressants, analgesics,

anti- inflammatory agents, antibacterials, antifungals, cardiovascular drugs, and diuretics.

Fifty-five different APIs are currently produced, combining both generic APIs and

patent protected APIs. The company has the expertise and resources to internally

manage all quality and compliance and regulatory affairs activities required for

custom and generic products.

Since 1960, FIS has filed more than 200 patent applications, primarily directed

at process innovation. Since 2007, FIS has adopted a more rigorous policy of

protection and enforcement of Intellectual Property Rights, increasing the number of

patent applications filed.

Visit Fabbrica Italiana Sintetici (FIS) Group at www.fisvi.com.

CML Invests to Support Late-Phase and Commercial API Demand in PharmaWith sluggishness in the pre-clinical pipelines the past few years, most companies

in the pre-clinical toxicology space have been through numerous quarterly reports

articulating the woes of the past quarter, and the optimism that the future brings.

What has been overlooked until recently is the strength of the late phase

pipelines. Funding has been robust to emerging and mid-sized pharma

companies that have compounds at, or past, phase 2 clinical trials.

Many contract API suppliers who have a strong base of assets to handle

programs from phase 2 through launch have seen growth in their portfolio of

API projects. And Cambridge Major Labs is no exception. In July 2012, CML

embarked on a major expansion of its large scale API plant in Wisconsin.

Scheduled to be complete in April, the expansion will increase CML’s large

scale capacity by nearly 30 percent, enabling more capacity for the large number

of phase 2 and phase 3 APIs in CML’s funnel. Having a supplier that can meet

the growing volume needs as APIs progress to commercialization is key to a

successful new product launch; no technical transfer is required, and the API

supply is effectively de-risked.

Over the next few years, once the clinical pipelines run their course, pre-clinical

companies will be back in full swing, and those that have assets to bring the next

wave of APIs to IND will enjoy feast rather than famine. However, the API suppliers

who have the assets and personnel to accomplish all of the above will be in the best

position to take these forward—all the way to commercial with no tech transfers

Visit Cambridge Major Labs at www.c-mlabs.com.

INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 7

Five Minutes With…Jordi RobinsonGlobal Head, Technical Business

Development

Navin Fluorine International

What are your major concerns within your market over the next two years?

The continuing fragility of the global

economy is a major concern for us here

at NFIL & MOL. A significant part of our

business is conducted within the biotech

sector of the pharmaceutical industry and

this sector, perhaps more than any other, is

dependent upon outside funding, often from venture capitalists, for continuation

of its operations. A continued weakness in the recovery will have a profound effect

on both the amount and type of investment venture capitalists are looking to make.

By its very nature, the development of new drug candidates is a high risk endeavor.

The industry needs investors who are prepared to think long-term and are prepared

to take higher risks. Our concern is that if the recovery remains weak, investors will

look to shift their support to companies with later-phase, and thereby lower risk,

candidates. This will inevitably have an impact on the overall number of new drug

candidates coming through.

Among the challenges facing the industry, which one do you think is the most pressing—and why?

The biggest challenge facing the industry is the difficulty in bringing new drug

candidates to market. A significant reason why the “patent cliff” poses such a big

problem for the industry, is the huge expense and complex regulatory requirements

to bring new products to market. Whether through greater partnering by the global

pharma companies with complimentary organizations within the biotech/virtual

pharma sector, through a more collaborative approach by the various regulatory

bodies across the globe, or simply developing a more open and constructive

relationship with outsourcing partners; the pharmaceutical industry as a whole

needs to make it a priority to reduce the time, and thereby the cost, of bringing a

new drug candidate to market.

What should be the common goals within the industry and/or marketplace?

My belief is that within the pharmaceutical industry there should be more

collaboration and less competition. Many companies still persist in trying to

complete work in-house when there are often external providers who would be

better placed to assist. I believe that wherever a need for a particular technology

exists and a company with demonstrable expertise can be found, collaboration

should always be viewed as the most appropriate first step. This does, of course,

place great responsibility on the partnering companies to demonstrate said expertise

but, provided they can deliver what the client is looking for and provided both

parties are open and honest at the outset about what they are looking to achieve,

See 5 Minutes With…Navin Fluorine page 11

8 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California

Siegfried Shows Revenue, Profitability GrowthActive worldwide in the primary and secondary

production of drugs, the Siegfried Group has

production facilities in Switzerland, Malta, and

the U.S. It develops and manufactures active

pharmaceutical ingredients for the research-

based pharmaceutical industry, as well as the

corresponding intermediate steps and controlled

substances, and provides development and

production services for drugs in finished-dosage

forms including sterile filling.

Siegfried offers expertise in customer

development for complex oral drug delivery systems,

co-product development, manufacturing and

licensing, as well as a portfolio of finished dosage

form products. Siegfried is active in both the primary

and secondary production of drugs.

The company develops and manufactures

active pharmaceutical ingredients for the research-

based pharmaceutical industry as well as the

corresponding intermediate steps and controlled

substances, and provides development, and

production services for drugs in finished dosage

forms including sterile filling.

At the end of 2011, Siegfried, which employs

800 people, reported annual sales of CHF 328

million. Siegfried Holding AG is listed on the Swiss

Exchange (SIX: SFZN). During the first half of 2012,

the Siegfried Group maintained revenue growth

and increased profitability while progressing with

the company strategy. Net sales increased by 2.9

percent.

Drug-product development and manufacturing is

provided at the company’s Zofingen, Switzerland,

and Malta locations. The Zofingen facility is

approved by Swiss Medic/FDA regulatory

authorities, and Malta is approved by Malta

Medicines regulatory authority. Company

strengths include solid oral dosage formulation

development expertise; innovative process

optimization and improvement; expertise in a

variety of different technologies; creative life-cycle

management approaches; cGMP formulation

scale-up, clinical trial manufacturing, and

production throughout whole product

lifecycle; dedicated project management

offering transparency, flexibility, and proactive

relationships; proactive product co-development

with selected partners; and quality and regulatory

compliance.

Siegfried maintains a compliance board with

qualified senior management for global compliance

along its value chain of drug substance and drug

product.

Visit Siegfried at www.siegfried.ch/.

Chiral Technologies Expands Services in AsiaThe life science services sector is growing rapidly in Asia,

as global pharmaceutical companies outsource work in

an effort to reduce costs and move medicines to market

faster. Following this market dynamic, Chiral Technolo-

gies has expanded its capabilities for medium-to-large

scale custom separation services in China and India.

“The demand for value-added separation services in Asia

is higher than ever as more global pharmaceutical companies

outsource their drug discovery studies to this region,” said

Dieter Heckmann, CEO of Chiral Technologies. “Chiral Tech-

nologies looks forward to assisting new and current global

customers with their custom separation projects, small to

large, in order to facilitate a faster and more economical path

to clinical trials and commercial development.”

The focus of Chiral Technologies’ custom separation

services is rapid and cost-effective production of

single enantiomer compounds. The company’s global

laboratories are equipped with high performance liquid

chromatography, supercritical fluid chromatography and

simulated moving bed chromatography systems.

With the availability of a portfolio of chiral stationary

phases, Chiral Technologies provides resolutions of chiral

compounds in quantities ranging from milligrams to multi-

kilograms. Visit Chiral Technologies at www.

chiraltech.com .

INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 9

Five Minutes With…Paul N. WituschekVice President, Global Business Development

& Client Services, Development and Clinical

Services

Catalent

What are your major concerns within your market over the next two years?

As pharmaceutical and biotech

companies continue to merge and evolve, their requirements in terms of being

able to get molecules to market quickly become increasingly complex. We have

seen this lead to longer decision making times, as companies evaluate their internal

capabilities vs the option to outsource one or more stages of the development, drug

delivery, or manufacturing life-cycle.

Among the challenges facing the industry, which one do you think is the most pressing—and why?

The increase in global regulatory requirements is universally challenging

throughout the pharmaceutical and biotech sectors. With each new guidance that

is introduced, companies have to quickly “come up to speed,” be compliant, and at

the same time try not to delay timelines. Changes may require new processes, costly

equipment, and a greater depth and breadth of expertise.

What is one relevant question (and your answer) that you believe no one is addressing adequately?

Q: How can we best address regulatory requirements as we progress the

development of our biologic or biosimilar product?

A: Global manufacturers are exploring the possibility of producing biosimilars

or follow-on biologics to extend product pipelines and increase the availability of

lower cost products. As biopharmaceuticals are relatively large, complex molecules,

manufacturing changes, even relatively minor ones, may alter clinical efficacy and

ultimately the safety of the biologic product—complicating their development. In

addition to the scientific challenges, companies are grappling with understanding

the regulatory aspects and current requirements for the development of biosimilars

destined for U.S. and European markets. Companies need to work closely with their

development, manufacturing, and regulatory partners to best understand how to

progress their biosimilar product and ensure successful product registration

What are two strategies—either personal or professional—you feel important to initiate this year?

Increasingly companies are looking for a strategic outsourcing partner that

provides pharmaceutical and biotech companies with the opportunity to collaborate

on global level to provide specialist skills and knowledge from the development

phase, all the way through registration to commercialization. An initiative that we

have recently launched is the Catalent Applied Drug Delivery Institute, which aims

See 5 Minutes With…Catalent page 17

10 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California

Phenomenex Meets the Needs of Preparative HPLC with Media and Method Development SupportDemand for the production of highly pure compounds continues to grow

in a wide range of industries. Phenomenex, a leader in chromatographic

media, offers several product lines to meet the needs of analytical and

preparative applications, including pharmaceutical, API, neutraceutical

and contract manufacturing and research organizations.

Five Phenomenex brands meet various purification needs. In

addition to bulk quantities for large-scale purification, many of the

Phenomenex media are available in the company’s proprietary Axia

preparative columns. This advanced column packing and hardware

design delivers extended lifetime, increased reproducibility and

efficiencies, improved peak shapes, increased loadability and stability

under high flow rates.

The Phenomenex Lux amylose and cellulose selectors provide a

variety of complementary selectivities for chiral compound

separation under reversed phase, polar organic, normal phase

and SFC conditions. Lux is available in bulk quantities for large-scale

purification as well as in Axia hardware, for simplified chiral separation

and purification.

Luna HPLC columns, packed with ultra-pure silica, are used for the

reversed phase separation of peptides and small molecules. Luna is

scalable from microbore to preparative and purification scale. Jupiter

columns are designed for the analysis and purification of biosimilars,

proteins and pegylated peptides. The Synergi line provides an alternative

selectivity for polar compounds and the Sepra family offers silica

solutions for low pressure and flash chromatography along with

polymeric solutions for oligonucleotide purification and ion exchange

chromatography.

Method Development and Optimization Services for Large-Scale PurificationMethod development and process optimization are critical to successful

large-scale chromatographic purification. PhenoLogix is a dedicated

Phenomenex analytical support laboratory that delivers customized

expertise and solutions with fast turnaround. Customers can send their

compounds to PhenoLogix and quickly receive fully optimized method

development recommendations—including media, mobile phase

conditions, theoretical loading, and yield. PhenoLogix can also take

an existing method and re-optimize it for better yield and purity and

time and cost savings. PhenoLogix also performs contract purification

services, in amounts up to .5 kilograms. In addition to reversed phase

chromatography and small molecule separations, PhenoLogix offers free

chiral screening services.

INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 11

it is my opinion that adopting a truly

integrated approach from an early

phase is the best way to reduce time,

cost, and risk.

What are two strategies—either personal or professional—you feel important to initiate this year? Cost-cutting? Additional capital expenditure? Additional marketing investments? Team building? More emphasis on social media?

Marketing is one area where we

at NFIL & MOL will be investing more

in 2013. We are companies with

significant experience and expertise

in fluorination chemistries and have

recently made substantial capital

investments in improving and adding to

our manufacturing facilities. We now

feel we are well positioned to support

projects at any stage of development

and this is the message we will be

taking to market in 2013. Fluorine is

an essential component of many drug

candidates but fluorination is a complex

and often hazardous chemistry to

undertake. We feel that it is important

that customers are aware that we are

a company that has both the relevant

expertise to solve their problems and

the appropriate facilities to support the

full life-cycle of their project.

Social media is another area

where NFIL & MOL will be making

an investment in 2013. Although

I still believe, from a business to

business perspective, social media

is still in its infancy, I do believe it is

becoming an increasingly important

tool for businesses within the industry.

Many global brands have embraced

the technology as a way of directly

engaging with their customers, mainly

in consumer products, but outside

of the major multi-nationals, most

companies in the chemical industry

have been reticent to commit resources

to developing their ‘social presence’. As

the next generation of graduates and

future business leaders come through

the system, people who regard social

media as an essential part of daily life,

it is precisely those companies who

act now that will be positioned as the

global brands of the future.

Navin Fluorine International (NFIL) &

Manchester Organics Ltd (MOL) are

high-quality manufacturers of speciality

organic building-blocks, with strong

expertise in fluorination at all scales of

operation.

From Navin page 7

New Tosoh Fluorine Fine Chemical LaunchedTosoh F-Tech has an addition to its

product line of fluorinating agents

and building block fluorine chemicals,

(Difluoromethyl)trimethylsilane. This

reagent incorporates a Difluoromethyl

group cleanly into a molecule without

unwanted impurities normally observed

from traditional fluorination methods.

In the presence of a Lewis base, (Difluo-

romethyl)trimethylsilane reacts with

aldehydes, ketones, and imines to give

the corresponding products in good to

excellent yields under mild conditions.

Introduction of highly electronega-

tive fluorine atoms into a molecule can

lead to a number of advantages. These

include a change in lipophilicity allow-

ing passage of the molecule through

the cell membrane, increased binding at

the active site, and increased bioavail-

ability as fluorinated molecules are

harder to metabolize.

Recently, pharmaceutical and

agrochemical companies have investigated

the substitution of the Trifluoromethyl

group with a Difluoromethyl group. Visit

Tosoh at www.tosohusa.com.

12 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California

Rieke Metals’ Expansion Provides Greater Depth in Product Availability For 21 years, Rieke Metals

has provided novel reagents

for drug discovery and material

science. The latest expansion

to its facility in Lincoln, Neb.,

allows for bulk quantities of

unique organozinc reagents

and specialized Grignard

reagents.

Founded in 1991, the

company offers a range of

technology based on highly

reactive metals, including

magnesium, zinc and

manganese. The exceptional

reactivity of these metals

allows the preparation of

novel organometallic reagents,

many displaying unusual

functionality.

Rieke zinc reacts directly

with alkyl, aryl, and vinyl halides and tolerates a broad range of functional groups,

such as chlorides, nitriles, esters, amides, ethers, sulfides and ketones. Also of

significance is that aryl halides show no scrambling of position when ortho-, meta-

or para-substituted substrates are used.

Rieke magnesium allows

the preparation of many

Grignard reagents that are

not possible using standard

magnesium methods. It can

allow Grignard formation at

lower temperatures, avoiding

decomposition or unwanted

additions. The advantages of

low-temperature Grignard

preparation include many

benzylic systems, which tend to

yield homocoupled products at

room temperature or above.

In addition to

organometallic compounds, the

facility proudly manufactures

more than 10,000 research

compounds and more than

350 thousand molecules under

research contract. Among these

fine organic chemicals are a large number of heterocyclic compounds.

Rieke Metals holds many patents in the area of semiconducting polymers and

offers regioregular and regiorandom P3HT in gram to kilogram quantities.

Visit Rieke Metals at www.riekemetals.com.

INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 13

Five Minutes With…John RiceExecutive Director

The Chemical Educational Foundation

Among the challenges that industry faces, which do you think are the most pressing?

A huge challenge to the industry is educating people, specifically youth, to under-

stand what the chemical industry achieves for them. Where would you be without

science? You definitely wouldn’t be down the street at Disneyland! Science is behind all

of the “magic” that Disney creates on a daily basis in the form of engineering new park

rides, creating animated movies—even down to food they serve in concession stands.

Do the millions of people that visit the park annually have even the slightest clue that sci-

ence, specifically technical innovation and physics, is the reason that favorite amusement

rides like Splash Mountain exist?

If you’re reading this, you most likely work for a chemical company and are well-versed

in the value that science and the industries that support it provide to man-kind on a daily

basis. The challenge is making sure that your stakeholders and community members are

also aware of these advantages. Ignoring this need for education creates a lack of under-

standing of the benefits that industry provides to the general public’s everyday lives. What

people don’t understand, they tend to fear, and that can result in overzealous regulation

that impacts industry as a whole, weakening the economy from top to bottom.

What should be the common goals within the industry and/or marketplace?

A common goal within industry should be educating constituents about the

vast benefits of science. It is industry’s responsibility to itself and society to take a

leading role in the advancement of science education initiatives. This direct involve-

ment will help eliminate the negative stigmas placed on the chemical industry and

create future generations of well-informed citizens. In any production process, what

we put in is central to the end result. For industry as a whole, getting involved in

efforts to improve the US education system should not be considered “community

outreach” or “philanthropy” but more as activities that are central to your “right to

do business” argument.

Many chemical companies are already involved. Industry management programs

such as the National Association of Chemical Distributors’ Responsible Distribution, the

American Chemistry Council’s Responsible Care, and, of course. SOCMA’s ChemStewards

program, are asking their member companies to make a commitment to improving

science education opportunities for our youth by placing greater emphasis on supporting

science, technology, engineering, and math (STEM) initiatives. Increasing these efforts and

the number of engaged companies should be the common goal among all industry.

CEF is a non-profit organization that works with the chemical industry to enhance

science education for students and educators in grades K-8. By emphasizing the

central role of chemistry in all the sciences and in oeveryday lives, CEF strives

to inspire future leaders in pursuing science-related careers and to improve the

overall understanding of, participation in, and appreciation of chemistry and

chemicals.

14 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California

Industrial Chromatography: Novasep Continues to Gain Momentum

The growing demand for

advanced purification on the

pharmaceutical market recently

has led Novasep to invest $40

million in a chromatography plant

at its Mourenx, France, site. This

new plant, designed by Novasep’s

in-house engineering team, will

include Varicol systems with 1,200

mm diameter columns operating at up to 70 bar.

Earlier last year, Novasep announced a $4 million investment in its Safebridge-

certified facility in Le Mans, France. This plant is dedicated to the production of

highly potent APIs from a few grams per day to tens of kilograms per week. The

new production facility will include large-scale industrial HPLC equipment and

increased capacities to the site’s current cGMP purification suites in confined

environments (OEL down to 0.03 µg.m-3.8h-1).

These investments in Le Mans and Mourenx, France, add capabilities to Novasep’s

worldwide purification platform with additional facilities in Shanghaï, China; Boothwyn,

Pa.; Pompey, France; and Chasse-sur-Rhône, France. This platform operates proprietary

preparative chromatography systems and relies on experienced process development and

engineering teams. Benefitting from a 15-year proven track record, it provides process

development as well as pilot and commercial scale manufacturing services.

Novasep provides its customers with insourcing or outsourcing solutions for the

purification of fine chemicals and active pharmaceutical ingredients at large scale.

Visit Novasep at www.novasep.com.

CU Chemie Uetikon Reactor on Task with Successful Production CampaignsCU Chemie Uetikon’s two new Cryogenic Reactor at its cGMP Plant in Lahr, Germany

has undergone first production campaigns successfully. The 100-liter (26 gallon) and

2,500-liter (660 gallon) reactors with the capability of reaching -80 °C -110 F°F) are ready

for additional new projects. These low temperature reaction vessels have completed CU

Chemie Uetikon’s investment at its cGMP Plant MPA P3 and its pilot plant

The company has finished the expansion of its multipurpose cGMP production

unit (MPA P3) and pilot plant in Lahr, Germany, and is now going full steam ahead.

Additional capacity for production of high value, late stage intermediates, and

pharmaceutical active ingredients is now available to small, emerging as well as

large pharmaceutical companies.

The cGMP plant has four independent operating production lines at its disposal,

enabling the customers to obtain premium quality products, which will satisfy the

requirements of the FDA and other regulatory agencies. Its total reactor capacity is

91.5 m3 (24,200 Gallons).

From pre-clinical through commercialization, CU Chemie Uetikon enables

customers to bring their products to market in the most efficient timeframe

possible. The Lahr team is particularly proud of its record in numerous FDA

inspections carried out since 1987. The last inspection in 2010 was passed, just like

the one before, without any adverse comments or forms 483 complaints.

Chemie Uetikon has particular expertise in high-pressure reactions (up to 100

bar/1,400 psi), hydrogenation, Grignard reactions, Carbonylation techniques, and a

complete range of small to large-scale technologies for chemical synthesis.

Visit Chemie Uetikon at www.uetikon.com.

INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 15

Euticals offers more than 200 active in-

gredients for different therapeutic areas

and about 600 advanced intermediates

via economically competitive processes

from kilograms to metric tons.

Of the 11 sites located in Europe

and the U.S. where its products and

services are offered, 10 of the sites

operate under cGMP rules, with

eight being FDA approved and one in

Springfield, MO, with a DEA permit for

controlled substances.

The challenges and rising costs of

doing business in the East (India and

China), compounded by the new EU

and USA laws will affect API sourcing

decisions. Euticals’ business model is

revolving around manufacturing in

the Western markets, such as Italy,

France, Germany, United Kingdom and

the U.S., where it has an established

manufacturing footprint.

As an increasing number of

products losing patent protection over

the next decade will be specialized,

Euticals is focusing on innovative and

cost effective processes, as well as

niche technologies for sustainable

sales growth in North America and

Emerging-pharma markets.

In API manufacturing, oncology APIs

are core product lines. The Italian sites

at Lodi and Varese produce HPAPIs and

cytotoxics from grams to commercial

scale. Both of these sites completed

capacity expansions in 2012. The

company also offers injectable dosage

forms for oncology from a Swiss joint-

venture site.

Euticals offers sterile aseptic API

facilities in France to accommodate

Band 3 and 4 compounds. It

has capacity for high potency

fermentation at Rozzano Italy

for immunosuppressants and

neuromuscular blocking agents, while

the Origgio, Italy, site offers the gamut

of APIs including tetracyclines. Euticals

also is a strong player in supporting

pharma generic customers for

paragraph IV and 505-2b filings with

innovative technologies.

The contract manufacturer has a

combination of a broad technological

base, particularly in the fields of

organometallic chemistry, heterocyclic

chemistry, enzymatic chemistry,

fermentation, and experience in

scale-up to commercial scale. With

commercial experience in transition

metal coupling reactions with boronic

acids and related chemistries, it makes

more than 150 boronic acids from

kilograms to several hundred metric

tons at sites in Germany, France, Italy,

and the U.S. These boronic acids range

from simple to highly functionalized,

and include aliphatic, aromatic, and

heterocyclic compounds. Visit Euticals

at www.euticals.com.

Euticals’ Products Offered from 11 Sites in Europe, U .S .

Albemarle Continues Expansion in PennsylvaniaAlbemarle, a global developer,

manufacturer and marketer of highly

engineered specialty chemicals and

services, announced today that its Fine

Chemistry Services (FCS) business has

approved and begun construction on

another expansion of its Tyrone, PA

custom manufacturing facility.

“This $30 million expansion

adds new capacity to the site for

custom manufacturing projects, but

more importantly, will improve the

infrastructure to allow for future

See Albemarle page 18

16 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California

Digital Specialty Earns Ligands LicenseDigital Specialty Chemicals—a manufacturer

of high quality organophosphorus and

organometallic chemicals known for its agility

to innovate and meet rigid timelines—has been

granted a worldwide license for the Buchwald

organophosphine ligands from M.I.T. The

license covers composition of matter and the

use of the ligands in metal-catalyzed processes.

With DSC’s interest in addressing requirements

of global pharmaceutical, specialty chemical

and semiconductor markets for efficient and

effective technologies, the license will give DSC’s

customers access to proven superior tools for

planned process chemistry and engineering milestones.

The Buchwald ligands, such as JohnPhos, BrettPhos, SPhos and XPhos, have

been utilized in a broad range of palladium-catalyzed coupling reactions, including

Heck, Suzuki, Buchwald-Hartwig, Sonogashira and alpha arylations. The Buchwald

family of ligands allow for coupling of inexpensive aryl chlorides, in addition to

the more typical aryl bromides, in the preparation of C-C, C-N, and C-O bonds.

Generally, the active catalyst is generated in-situ from the ligand and a palladium

species.

“The addition of the Buchwald ligands to our existing range of chiral and

achiral phosphine ligands broadens the solutions we can offer to our customers

for coupling chemistry,” states Christine Harnett, VP of business development

pharma. “These products are an excellent fit for DSC with our core competency in

organophosphorus chemistry and our expertise in scale-up of synthetic processes.”

Visit Digital Specialty Chemicals at www.digitalchem.com.

Christine Harnett

RightAnswer .com Doubles EHS Data Sources, Announces Mobile InterfaceRightAnswer.com, headquartered in Midland, MI, has seen significant growth

in the last 12 months. Recognized by EHS specialists worldwide as a reliable

source for current chemical, MSDS, reproductive risk, and regulatory compliance

information, RightAnswer’s ChemKnowledge and RegsKnowledge Systems provide

comprehensive information from proprietary and licensed databases.

“In 2012, we doubled our data sources so our clients have access to even more

in-depth chemical data in an integrated combination that they won’t find anywhere

else,” said Glen Markham, who manages corporate business development for

RightAnswer. “This includes exclusive, proprietary content. Also, the information is

continuously updated from trusted sources and mastered to provide our users with

an unmatched, single-search simplicity.”

RightAnswer says it is committed to providing customers with the knowledge

to help: meet EHS requirements; prepare for chemical use and approvals; make

emergency response evaluations; assess toxicology risks; implement regulatory

compliance; author MSDSs, labels, and other documents; and optimize product

stewardship management.

Another soon-to-be launched innovation is the OnHand mobile interface from

RightAnswer, being released this month.

“All of the integrated data and functionality of our OnLine Application is

now optimized for smartphones and tablets with RightAnswer’s new OnHand

mobile interface,” said Markham. “This new interface supports easy access to

RightAnswer’s Knowledge Solutions in the office or on the go.”

For more information, visit www.RightAnswer.com.

INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 17

to promote innovation, knowledge

sharing and collaboration between

industry leaders, academic experts,

customers and regulators, to enhance

understanding of available, emerging,

and future drug delivery technologies,

while improving patient care. The

institute will develop programs

that facilitate mutually beneficial

collaborations, increase communication,

and shed light on key regulatory

issues affecting drug developers and

researchers.

Catalent Pharma Solutions is a global

leader in development solutions and

advanced drug delivery technologies,

providing worldwide clinical and

commercial supply capabilities for

drugs, biologics, and consumer health

products.

From Catalent page 9

ZaCH Brings Innovation Out of TraditionZaCh is a fine chemicals company

dedicated to providing its customers

with fast, cost-effective, quality

custom synthesis services, APIs, and

intermediates—offers extensive process

development support.

With more than 350 patents

covering chemical processes and

intermediates and a sustained strategy

of developing, implementing and

protecting technological innovation,

its research teams develop and apply

new and cost-effective processes for

the production of active pharmaceutical

ingredients (APIs) and advanced

intermediates.

Its worldwide presence has grown

to two cGMP production facilities—in

Lonigo, Italy, and Avrillè, France. In

addition to manufacturing capability,

each facility contains dedicated R&D

and commercial activities for custom

synthesis and generic API production.

The FDA-inspected facilities are

compliant with national/international

regulations.

Visit ZaCh Systems at www.

zachsystem.com.

18 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California

incremental and low-cost expansions as we gain new projects from customers. This

rapid response and flexibility are hallmarks of the Tyrone operating culture,” said

Randy Andrews, Tyrone site manager.

“We are pleased once again to expand the Tyrone site to serve the growing product

needs of our customers. This expansion comes shortly after our earlier expansion that

began operation in November 2012 and will fuel the continued growth of FCS’s custom

manufacturing business. We are anxious to take advantage of the eventual 40% increase

in reactor capacity. The first increment of new capacity will be operational late in the first

quarter of 2014,” said David DeCuir, FCS Business Director.

About Albemarle Albemarle Corporation, headquartered in Baton Rouge,

Louisiana, is a leading global developer, manufacturer, and marketer of highly-engineered

specialty chemicals for consumer electronics, petroleum refining, utilities, packaging, con-

struction, automotive/transportation, pharmaceuticals, crop protection, food-safety and

custom chemistry services. The Company is committed to global sustainability and is ad-

vancing its eco-practices and solutions in its three business segments, Polymer Solutions,

Catalysts and Fine Chemistry. Corporate Responsibility Magazine selected Albemarle to its

prestigious “100 Best Corporate Citizens” list for 2010 and 2011.

Albemarle employs approximately 4,000 people and serves customers in

approximately 100 countries. Albemarle regularly posts information to www.

albemarle.com, including notification of events, news, financial performance,

investor presentations and webcasts, Regulation G reconciliations, SEC filings, and

other information regarding the Company, its businesses and the markets we serve.

Visit Albemarle’s FCS division at www.albemarle.com/fcs.

From Albemarle page 15

explained that Rx-360’s mission is to “educate—but not lobby” in the process of

protecting patient safety.

The organization shares information and develops processes related to the integrity of

the healthcare supply chain and the quality of materials within the supply chain.

The four-year-old Rx-360 aims to increase its membership this year by 20 percent

in order to have “eyes and ears on the ground” all over the world to understand

regulatory requirements and keep manufacturers, suppliers, and observers engaged

with one another.

Panelists agreed that the cumbersome and disparate official tracking forms are

a particularly thorny issue. “We’re a small piece of some of our suppliers’ business,

but they need to acknowledge our requirements,” said David McCarthy, senior

director of worldwide procurement of Pfizer. “They’re not eager to come up with

a separate quality agreement for our situation, but now Rx-360 has a standardized

agreement on its website (www.rx360.org). With a standard template, nobody in

this situation has to reinvent the wheel.”

Auditing is critical, and Kim Cauchy, VP of global sourcing at Mylan, warned that

pharmaceutical companies must be vigilant to the extent that they should “audit

suppliers and audit suppliers’ auditing programs.”

McCarthy emphasized that pharmaceutical company scientists should engage

more in supply chain auditing, while Tom Beil, VP of quality and regulatory affairs at

Sigma/Alrich/SAFC, advocated that suppliers be educated “at the molecular level.”

Keeping up with regulatory requirements was another concern. Tony

Weiderhold, consultant for development and commercial API sourcing at Eli Lilly and

Co., explained, “We need to weigh security against transparency and understand

why regulations are being developed.”

Another critical issue revolves around supply chain security, which is often

subjected to political challenges. Beil suggested developing a long-term strategy

for monitoring procedures instead of developing one case-by-case with suppliers.

William Reis, VP of global strategic sourcing at Amgen, opined that such situations

“reinforce the importance of Rx-360 to share information quickly and put out best

practices.”

“Rx-360 is about coming together to solve problems,” Watson concluded.

From Rx-360 page 1

There are two kinds of intangibles. Off-balance-sheet assets, which exist now,

include customer lists, patents, brand names, software, and tooling. Goodwill

is a function of the company’s future potential. “It’s important to show growth

potential,” Oppenheimer added.

Oppenheimer method to evaluate a business starts with the organizational

structure and a chart that illustrates that the business is a going concern

that will continue—even if the owner is present. The financial statements,

adjusting expenses such as travel and real estate for profitability, are the next

part of the equation.

The marketing/marketing research section is the most telling, because it

substantiates the company’s future potential. The final evaluation comprises tthe

balance sheet equity and the goodwill and projects where the company will be in

five years.

The evaluation package can be used as a prospectus or give the seller ideas

to add value to the business. Oppenheimer uses a targeted approach to find

buyers, sends out the package, and then gets legal experts to draft the purchase

agreement.

“Go through a defined exit plan instead of spinning wheels and not getting the

right price,” Oppenheimer advised.

Neal McCarthy, managing director of Fairmount Partners, which provides

financial advisory services to support the sale of all types of businesses, including

both family owned businesses, partnerships, private equity sponsored businesses

and corporate divestitures, targeted his talk to pharmaceutical executives who are

considering the sale of their businesses.

Typically, Fairmount’s clients have built value by first establishing strong positions

in their market, and are looking for a way to maximize shareholder value for the

long-term, whether it is through an acquisition, a capital raise, or a sale of the

company.

The company’s understanding of the value creation process at each stage of its

development, combined with its transactional knowledge, enables Fairmount to

provide timely advice on strategy, valuation, transaction structure, and relevant

prospects.

Knowing the right time to sell a business, whether to sell it to a financial buyer

or an industry buyer, and prepare for a transaction to achieve a smooth transition

are key elements, McCarthy said.

Planning ahead—by as much as five years—is the key to a successful transaction,

both experts agreed.

From To Sell or Not page 1

INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 19

C&EN’s Wrap Party: A Toast to InformexUSA 2013

20 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California

Showcase Snap Shots

Scott A. Miller, head, special projects, Carbogen Amcis

Herve Limouzin, sales director, Pierre Fabre

Felix Chen, sales director, global operations, CAC Group

Hugh McManus, director, business development, Dottikon ES

Doug Cochran, VP, business development, Optima Chemical

Sandra Moro, deputy director, business development USA,

Helsinn

John Brice, senior director, business development,

Asymchem John Michnick, associate director, West Coast sales, Cambrex

Wayne Nowicki, director, business development,

Regis TechnologiesJoseph D’Antuono, account

director, North America, Evonik

Showcase attendees

INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California 21

A d v e r t i s e r s I n d e xAMPAC Fine Chemicals, Booth 2257, www.ampacfinechemicals.com . . . . . 2

Ash Stevens, Inc., Booth 1552, www.ashstevens.com . . . . . . . . . . . . . . Cover

BioVectra Inc., Booth 2156, www.biovectra.com . . . . . . . . . . . . . . . . . . . . . 6

Cambridge Major Laboratories, Inc., Booth 2225, www.c-mlabs.com . . . 15

C&EN, Booth 2447, cen.acs.org . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 14, 16

Chemtura Corp., Booth1548, www.chemtura.com . . . . . . . . . . . . . . . . . . 6

DFI Pharma, Booth 1545, www.dfipharma.com . . . . . . . . . . . . . . . . . . . . . . 7

Evonik, Booth 1238, www.evonik.com/pharma . . . . . . . . . . . . . . . . . . . . . 23

Fabbrica Italiana Sintetici SpA, Booth 2049, fisvi.com . . . . . . . . . . . . . . . . 9

Federal Equipment Co., Booth 2030, www.fedequip.com . . . . . . . . . . . . 13

Helsinn Advanced Synthesis S.A., Booth 1809, www.helsinn.com . . . . . . . 8

J-Star, Booth 1343, www.jstar-research.com . . . . . . . . . . . . . . . . . . . . . . . 10

LIST USA Inc., Booth 2419, www.list.us . . . . . . . . . . . . . . . . . . . . . . . . . . . 17

Nova Molecular Technologies, Inc., Booth 1442, www.novamolecular.com . 7

Oakwood Products, Inc., Booth 1109, www.oakwoodchemical.com . . . . 21

Organic Technologies, Booth 1247, www.organictech.com . . . . . . . . . . . 10

PCI Synthesis.com, Booth 1059, www.pcisynthesis.com . . . . . . . . . . . . . . 12

PharmaCore, Inc., Booth 1303, www.pharmacore.com . . . . . . . . . . . . . . . 11

Ricerca Biosciences, Booth 2060, www.ricerca.com . . . . . . . . . . . . . . . . . 17

Siegfried USA, Inc., Booth 1101, www.siegfried.ch . . . . . . . . . . . . . . . . . . 12

Umicore AG & Co. KG, Booth 1131, www.umicore.com . . . . . . . . . . . . . . . 5

Zach Stystem S.P.A., Booth1701, www.zachsystem.com . . . . . . . . . . . . . . 14

Pope Scientific’s Distillation Contract Services For Heat Sensitive MaterialsPope Scientific specializes in high-

vacuum distillation toll processing

services for heat-sensitive materials.

Operations include molecular (short-path)

distillation, evaporation, concentration,

devolitilization, deodorization,

and hybrid wiped-film/fractional

column distillation. Typical examples

include separation and purification

of pharmaceuticals, intermediates,

biomaterials, vitamins, nutraceuticals,

cosmetics, edible and essential oils, esters,

fine chemicals, solvents, foods, flavors,

fragrances, polymers, extracts, waxes,

monoglycerides, and silicones.

New developments in “hybrid

distillation” allow fractional separations

of materials close in boiling point, even

when heat sensitive.

The new facility is licensed

for food processing, certified for

Kosher processing, and capable of

cGMP operation. Feed lots from liters to truckloads are handled with

rapid turnaround, minimizing client’s risk, time-to-market and development

costs. Professional experienced staff assures quality processing, proper

documentation and confidentiality.

In addition, feasibility testing services

are offered, utilizing Pope’s two-inch

and larger wiped film stills, set up in

configurations appropriate for the

process. GC and other instruments can

be utilized for in-process analyses as

required. Confidential reports with all

data are presented.

Pilot plant processing is offered for

scale-up rate studies, process strategy

development, production of small

pail and drum lots for client sample

distribution, and practical finished

product testing.

Combined lab and pilot scale studies

can lead to a comprehensive set of

knowledge enabling preparation for large

scale contract processing campaigns as

well as specification and design of turnkey

distillation equipment for manufacturing

and sale to clients. In many cases, the overall

resulting system is comprised of multiple stages of various units, including molecular stills,

evaporators, hybrid fractional stills and/or passive degasser units.

Visit Pope Scientific at www.popeinc.com.

22 INFORMEX Post Show Daily | FEBRUARY 2013 | Anaheim Convention Center Anaheim California

Exhibitors Light Up Convention

http://www.evonik.com/pharma